336 related articles for article (PubMed ID: 30325496)
1. Epistaxis in the setting of antithrombotic therapy: A comparison between factor Xa inhibitors, warfarin, and antiplatelet agents.
Glikson E; Chavkin U; Madgar O; Sagiv D; Nakache G; Yakirevitch A; Wolf M; Alon EE
Laryngoscope; 2019 Jan; 129(1):119-123. PubMed ID: 30325496
[TBL] [Abstract][Full Text] [Related]
2. The Impact of Traditional Anticoagulants, Novel Anticoagulants, and Antiplatelets on Epistaxis.
Yaniv D; Zavdy O; Sapir E; Levi L; Soudry E
Laryngoscope; 2021 Sep; 131(9):1946-1951. PubMed ID: 33533493
[TBL] [Abstract][Full Text] [Related]
3. Shorter hospital stays in epistaxis patients with atrial fibrillation when taking rivaroxaban or apixaban versus phenprocoumon.
Stankovic P; Georgiew R; Frommelt C; Hammel S; Wittlinger J; Hoch S; Obradovic D; Dagres N; Wilhelm T
J Thromb Thrombolysis; 2019 Apr; 47(3):384-391. PubMed ID: 30729376
[TBL] [Abstract][Full Text] [Related]
4. Volume and Characteristics of Intracerebral Hemorrhage with Direct Oral Anticoagulants in Comparison with Warfarin
.
Adachi T; Hoshino H; Takagi M; Fujioka S;
Cerebrovasc Dis Extra; 2017; 7(1):62-71. PubMed ID: 28376486
[TBL] [Abstract][Full Text] [Related]
5. Non-major bleeding with apixaban versus warfarin in patients with atrial fibrillation.
Bahit MC; Lopes RD; Wojdyla DM; Held C; Hanna M; Vinereanu D; Hylek EM; Verheugt F; Goto S; Alexander JH; Wallentin L; Granger CB
Heart; 2017 Apr; 103(8):623-628. PubMed ID: 27798052
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation.
Yao X; Abraham NS; Sangaralingham LR; Bellolio MF; McBane RD; Shah ND; Noseworthy PA
J Am Heart Assoc; 2016 Jun; 5(6):. PubMed ID: 27412905
[TBL] [Abstract][Full Text] [Related]
7. Management of anticoagulation with rivaroxaban in trauma and acute care surgery: Complications and reversal strategies as compared to warfarin therapy.
Myers SP; Dadashzadeh ER; Cheung J; Alarcon L; Kutcher M; Brown JB; Neal MD
J Trauma Acute Care Surg; 2017 Mar; 82(3):542-549. PubMed ID: 28045742
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation and Previous Stroke or Transient Ischemic Attack.
Coleman CI; Peacock WF; Bunz TJ; Alberts MJ
Stroke; 2017 Aug; 48(8):2142-2149. PubMed ID: 28655814
[TBL] [Abstract][Full Text] [Related]
9. Warfarin and Newer Agents: What the Oral Surgeon Needs to Know.
Steed MB; Swanson MT
Oral Maxillofac Surg Clin North Am; 2016 Nov; 28(4):515-521. PubMed ID: 27624772
[TBL] [Abstract][Full Text] [Related]
10. Gastrointestinal bleeding risk of non-vitamin K oral anticoagulants is similar to warfarin - a Japanese retrospective cohort study
.
Shirai T; Yamamoto T; Kawasugi K; Kuyama Y; Kita H
Int J Clin Pharmacol Ther; 2016 Nov; 54(11):841-846. PubMed ID: 27569738
[TBL] [Abstract][Full Text] [Related]
11. Association of Novel Oral Antithrombotics With the Risk of Intraocular Bleeding.
Uyhazi KE; Miano T; Pan W; VanderBeek BL
JAMA Ophthalmol; 2018 Feb; 136(2):122-130. PubMed ID: 29242919
[TBL] [Abstract][Full Text] [Related]
12. Four-factor Prothrombin Complex Concentrate for Reversal of Factor Xa Inhibitors versus Warfarin in Life-threatening Bleeding.
Rech MA; Masic D; Hammond DA
West J Emerg Med; 2021 Feb; 22(2):163-169. PubMed ID: 33856296
[TBL] [Abstract][Full Text] [Related]
13. Epistaxis in anticoagulated patients: Fewer hospital admissions and shorter hospital stays on rivaroxaban compared to phenprocoumon.
Sauter TC; Hegazy K; Hautz WE; Krummrey G; Ricklin ME; Nagler M; Borner U; Exadaktylos AK
Clin Otolaryngol; 2018 Feb; 43(1):103-108. PubMed ID: 28510336
[TBL] [Abstract][Full Text] [Related]
14. Retrospective comparison of low molecular weight heparin vs. warfarin vs. oral Xa inhibitors for the prevention of recurrent venous thromboembolism in oncology patients: The Re-CLOT study.
Alzghari SK; Seago SE; Garza JE; Hashimie YF; Baty KA; Evans MF; Shaver C; Herrington JD
J Oncol Pharm Pract; 2018 Oct; 24(7):494-500. PubMed ID: 28714376
[TBL] [Abstract][Full Text] [Related]
15. Anti Xa oral anticoagulants inhibit in vivo platelet activation by modulating glycoprotein VI shedding.
Pignatelli P; Pastori D; Bartimoccia S; Menichelli D; Vicario T; Nocella C; Carnevale R; Violi F
Pharmacol Res; 2016 Nov; 113(Pt A):484-489. PubMed ID: 27693274
[TBL] [Abstract][Full Text] [Related]
16. Bleeding risk of apixaban, dabigatran, and low-dose rivaroxaban compared with warfarin in Japanese patients with non-valvular atrial fibrillation: a propensity matched analysis of administrative claims data.
Kohsaka S; Murata T; Izumi N; Katada J; Wang F; Terayama Y
Curr Med Res Opin; 2017 Nov; 33(11):1955-1963. PubMed ID: 28857611
[TBL] [Abstract][Full Text] [Related]
17. Abnormal vaginal bleeding in women with venous thromboembolism treated with apixaban or warfarin.
Brekelmans MP; Scheres LJ; Bleker SM; Hutten BA; Timmermans A; Büller HR; Middeldorp S
Thromb Haemost; 2017 Apr; 117(4):809-815. PubMed ID: 28180233
[TBL] [Abstract][Full Text] [Related]
18. Comparison of effectiveness and safety of treatment with apixaban vs. other oral anticoagulants among elderly nonvalvular atrial fibrillation patients.
Deitelzweig S; Luo X; Gupta K; Trocio J; Mardekian J; Curtice T; Lingohr-Smith M; Menges B; Lin J
Curr Med Res Opin; 2017 Oct; 33(10):1745-1754. PubMed ID: 28849676
[TBL] [Abstract][Full Text] [Related]
19. Regarding epistaxis in the setting of antithrombotic therapy: A comparison between factor Xa inhibitors, warfarin, and antiplatelet agents.
Ali K; Wang JJ
Laryngoscope; 2019 May; 129(5):E160. PubMed ID: 30724350
[No Abstract] [Full Text] [Related]
20. In response to Epistaxis in the setting of antithrombotic therapy: A comparison between factor Xa inhibitors, warfarin, and antiplatelet agents.
Glikson E
Laryngoscope; 2019 May; 129(5):E161. PubMed ID: 30724345
[No Abstract] [Full Text] [Related]
[Next] [New Search]
